Courier Capital LLC lifted its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 21.5% during the 3rd quarter, Holdings Channel reports. The firm owned 50,348 shares of the biopharmaceutical company’s stock after acquiring an additional 8,925 shares during the period. Courier Capital LLC’s holdings in Bristol-Myers Squibb were worth $3,209,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of BMY. Tradewinds Capital Management LLC lifted its holdings in Bristol-Myers Squibb by 34.6% during the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 500 shares in the last quarter. Atlantic Trust LLC bought a new position in Bristol-Myers Squibb during the second quarter worth about $111,000. American National Bank lifted its holdings in Bristol-Myers Squibb by 11.7% during the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 225 shares in the last quarter. Blue Chip Partners Inc. lifted its holdings in Bristol-Myers Squibb by 0.7% during the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 15 shares in the last quarter. Finally, BDO Wealth Advisors LLC bought a new position in Bristol-Myers Squibb during the second quarter worth about $123,000. Institutional investors and hedge funds own 69.67% of the company’s stock.
Shares of Bristol-Myers Squibb Co (BMY) opened at $62.47 on Friday. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $102,240.00, a PE ratio of 24.59, a P/E/G ratio of 2.22 and a beta of 1.18. Bristol-Myers Squibb Co has a 12-month low of $46.01 and a 12-month high of $66.10.
The business also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be given a $0.40 dividend. The ex-dividend date of this dividend is Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.56%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s payout ratio is currently 62.99%.
Several research analysts have weighed in on BMY shares. Citigroup set a $72.00 target price on Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Wednesday, October 25th. Jefferies Group reiterated a “buy” rating and set a $72.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, September 27th. Vetr upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.50 target price on the stock in a report on Wednesday, September 27th. UBS Group reiterated a “buy” rating and set a $72.00 target price (up from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. Finally, SunTrust Banks upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Monday, October 30th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $65.05.
In related news, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the sale, the executive vice president now owns 9,251 shares of the company’s stock, valued at $585,033.24. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Theodore R. Samuels II bought 4,000 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was bought at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the transaction, the director now owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by insiders.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
What are top analysts saying about Bristol-Myers Squibb? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bristol-Myers Squibb and related companies.